Temoporfin
Foscan (temoporfin) is a small molecule pharmaceutical. Temoporfin was first approved as Foscan on 2001-10-24. It has been approved in Europe to treat head and neck neoplasms and squamous cell carcinoma.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
| Cholangiocarcinoma | D018281 | C22.1 | — | 1 | — | — | — | 1 | |
| Klatskin tumor | D018285 | EFO_1001005 | — | 1 | — | — | — | 1 | |
| Squamous cell carcinoma of head and neck | D000077195 | — | 1 | — | — | — | 1 | ||
| Nasopharyngeal neoplasms | D009303 | — | 1 | — | — | — | 1 | ||
| Head and neck neoplasms | D006258 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma | D002294 | — | — | — | — | 1 | 1 | ||
| Tongue neoplasms | D014062 | EFO_0003871 | C02.9 | — | — | — | — | 1 | 1 |
| Verrucous carcinoma | D018289 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TEMOPORFIN |
| INN | temoporfin |
| Description | Temoporfin is a member of chlorins. It has a role as a photosensitizing agent. |
| Classification | Small molecule |
| Drug class | benzoporphyrin derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc2CC4)C=C3)c1 |
Identifiers
| PDB | — |
| CAS-ID | 122341-38-2 |
| RxCUI | 115243 |
| ChEMBL ID | CHEMBL383675 |
| ChEBI ID | — |
| PubChem CID | 60751 |
| DrugBank | DB11630 |
| UNII ID | FU21S769PF (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,046 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,922 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more